Novo Nordisk reports Phase 3 GLP1 results for children
Novo Nordisk said it has successful results from a Phase 3 study of its injectable GLP1 drug for children, as GLP1 weight-loss drugs are not yet approved for this group.
Novo Nordisk said Monday that its injectable GLP1 drug delivered successful results in a Phase 3 study in children, while the company’s weight-loss medicines remain unapproved for that obesity group.